Oncternal Therapeutics (ONCT)
(Real Time Quote from BATS)
$7.21 USD
+0.21 (3.06%)
Updated Jul 22, 2024 03:17 PM ET
3-Hold of 5 3
F Value C Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ONCT 7.21 +0.21(3.06%)
Will ONCT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ONCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ONCT
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
All You Need to Know About Oncternal Therapeutics (ONCT) Rating Upgrade to Buy
ONCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for
Oncternal Therapeutics (ONCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates
Other News for ONCT
One new option listing and eighteen option delistings on July 22nd
Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
Analysts Offer Insights on Healthcare Companies: Springworks Therapeutics (SWTX), Cyclo Therapeutics (CYTH) and Oncternal Therapeutics (ONCT)
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer